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co-occurrence
Sander Canisius1, John W. M. Martens2 and Lodewyk F. A. Wessels1,3,4*
Abstract
In cancer, mutually exclusive or co-occurring somatic alterations across genes can suggest functional interactions.
Existing tests for such patterns make the unrealistic assumption of identical gene alteration probabilities across
tumors. We present Discrete Independence Statistic Controlling for Observations with Varying Event Rates
(DISCOVER), a novel test that is more sensitive than other methods and controls its false positive rate. A pan-cancer
analysis using DISCOVER finds no evidence for widespread co-occurrence, and most co-occurrences previously
detected do not exceed expectation by chance. Many mutual exclusivities are identified involving well-known genes
related to cell cycle and growth factor signaling, as well as lesser known regulators of Hedgehog signaling.
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Background
Tumor development emerges from a gradual accumula-
tion of somatic alterations that together enable malignant
growth. As has been revealed by recent genomic profiling
efforts, an immense diversity exists in the alterations that
tumors acquire [1, 2]. Whether by e.g., copy number aber-
ration, point mutation, or DNAmethylation, alterations of
many genes may potentially trigger transformation. Often
though, the fate of a cell acquiring a certain alteration
depends on other alterations already present [3]. There-
fore, with an ever-expanding catalog of cancer genes, a
need arises to establish how alterations in those genes
interact to transform healthy cells to cancer cells. This
task can be approached by statistical analyses aiming to
uncover more complex, combinatorial patterns in somatic
alterations.
Two such patterns are co-occurrence and mutual exclu-
sivity. In the former, alterations of certain combinations
of genes tend to co-exist in the same tumor, whereas
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in the latter, mostly only one out of a group of genes
is altered in a single tumor. Mutual exclusivity is fre-
quently observed in cancer genomics data [4, 5]. Individ-
ual alterations targeting similar biological processes are
believed to be mutually redundant, with one alteration
being sufficient to deregulate the affected process. Iden-
tifying mutual exclusivity can therefore help in finding
unknown functional interactions. With this in mind, sev-
eral statistical methods have been proposed to identify
significant patterns of mutual exclusivity [6–12].
Just as mutual exclusivity is interpreted as a sign of
redundancy, co-occurrence is often held to entail syn-
ergy. Alteration of only one of the two genes would be
relatively harmless, whereas cells with alterations in both
progress to malignancy. If such synergy exists, cancer
genomes should be enriched for these co-alterations; i.e.,
tumors harboring alterations in both genes should be
more frequent than expected by chance. Several stud-
ies have reported an abundance of co-occurring somatic
alterations in various types of cancer [13–19]. For somatic
copy number changes, however, it has also been suggested
that co-occurring alterations emerge from tumors’ overall
levels of genomic disruption [20]. Indeed, tumors dis-
play a wide diversity in genomic instability, both across
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and within cancer types. In tumors harboring many alter-
ations, one should not be surprised to see simultane-
ous alterations in any pair of genes. In contrast, two
genes altered in a tumor carrying a small number of
alterations might instead have resulted from a purifying
selective process. Suggesting synergy as an explanation
for observed co-occurrence is only reasonable if a sim-
pler explanation like tumor-specific alteration rates can be
rejected.
In this paper, we address the statistical implications
of heterogeneous alteration rates across tumors for co-
occurrence and mutual exclusivity detection. With exten-
sive analyses of simulated data, we show how commonly
used statistical tests are not equipped to deal with the
mismatch between what is assumed by the test and what
is encountered in the data. In the presence of heteroge-
neous alteration rates, countless spurious co-occurrences
are picked up in data that are controlled not to contain
any. At the same time, many instances of true mutual
exclusivity are missed. Based on these observations, we
introduce DISCOVER, a novel statistical independence
test that incorporates the overall alteration rates of tumors
to successfully solve the issues encountered with exist-
ing tests. We compared the performance of DISCOVER
to that of several other published mutual exclusivity tests:
MEMo [6],muex [8],mutex [9],CoMEt [10],MEGSA [11],
and TiMEx [12]. Across the whole range of significance
levels, DISCOVER is more sensitive while controlling the
false positive rate at the specified level.
We also applied DISCOVER to a selection of more than
3000 tumors across 12 different cancer types. Only one
co-occurrence was detected that is not explained by over-
all rates of alteration alone. On the other hand, manymore
cases of mutual exclusivity were detected than would have
been possible with traditional tests. The genes targeted by
these alterations cover many of the core cancer pathways
known to display such exclusivity. However, we also iden-
tified exclusivity among less canonical actors in the cell
cycle, and among regulators of Hedgehog signaling.
Results
Common tests for co-occurrence or mutual exclusivity
assume homogeneous alteration rates
A commonly used test for both co-occurrence and mutual
exclusivity is Fisher’s exact test applied to a 2 × 2 con-
tingency table [16–18]. The test is used to support co-
occurrence when the number of tumors with alterations in
both genes is significantly higher than expected by chance.
Likewise, it suggests mutual exclusivity when the number
of tumors with alterations in both genes is significantly
lower. The validity of this test depends on the assump-
tion that genes’ alterations across tumors are independent
and identically distributed (i.i.d.). Identical distribution
implies that the probability of an alteration in a gene is
the same for any given tumor. With cancer’s heterogeneity
in mind, this assumption may prove problematic. Surely,
a gene is more likely found altered in tumors with many
somatic alterations overall, than in tumors with only few
such changes.
Other tests used for co-occurrence or mutual exclu-
sivity depend on the same i.i.d. assumption as described
for Fisher’s exact test. This is the case for permutation
tests that estimate the expected number of tumors altered
in both genes by randomly reassigning gene alterations
across tumors [7, 13]. It is also true for a simple bino-
mial test that we will use to illustrate the consequences
of violating the i.i.d. assumption. This test is depicted in
Fig. 1c. The alteration probability pi of a gene is estimated
to be the proportion of tumors altered in that gene. For
example, gene 3 in Fig. 1a is altered in 2 of the 5 tumors,
resulting in p3 = 0.4 (Fig. 1c). If alterations targeting two
genes are independent, the probability of a tumor altered
in both genes equals the product p1 · p2 of those genes’
alteration probabilities. Hence, out of m tumors, m · p1p2
tumors are expected to harbor alterations in both genes.
In the example in Fig. 1a, the probability of alterations
in both genes 3 and 5 would be p3 · p5 = 0.4 · 0.4 =
0.16. Therefore, if alterations of genes 3 and 5 were inde-
pendent, we would expect 5 · 0.16 = 0.8 tumors with
alterations in both. Observing more such tumors suggests
co-occurrence, whereas observing fewer suggests mutual
exclusivity (Fig. 1b).
Assuming homogeneous alteration rates leads to invalid
significance estimates
To illustrate the effect of the i.i.d. assumption on the
detection of mutual exclusivities and co-occurrences, we
performed analyses on simulated data. Genomic alter-
ations were generated such that the alteration frequencies
both per gene and per tumor resemble those observed in
real tumors, but without any designed relation between
the genes’ alterations; i.e., genes were simulated to be
independent. As these simulated data do not contain co-
occurrences or mutual exclusivities, all identified depar-
tures from independence are by definition spurious. We
can therefore use these data to check the validity of
the binomial test. When testing many pairs of indepen-
dently altered genes, a valid statistical test should produce
P values that approximately follow a uniform distribu-
tion. In contrast, when we test for co-occurrence in these
data, the P-value distribution shows a large skew towards
extremely low values (Fig. 2a). Even highly conservative
significance levels will mark the majority of gene pairs as
significant hits. Given that no true co-occurrences exist
in the simulated data, all these hits are false positives.
If we test for mutual exclusivities instead, we observe
a skew towards the high end of the P-value spectrum
(Fig. 2c).
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Fig. 1 Overview of the DISCOVER method. a The input to the method is a binary alteration matrix with genes in the rows and tumors in the
columns. The following panels illustrate how the two genes highlighted in red and green are tested for co-occurrence. b To identify co-occurrences
or mutual exclusivities, a null distribution is estimated that describes the overlap in alterations of two genes expected by chance. Co-occurrence and
mutual exclusivity correspond to the tails of this distribution. c In the binomial model, a single alteration probability is estimated per gene that
applies to all tumors. The expected number of alterations per gene matches the observed number. The expected number of alterations per tumor
does not match the observed number. The product of two genes’ alteration probabilities gives the probability of overlap by chance, which
multiplied by the number of tumors gives the expected number of tumors with alterations in both genes, in this case 0.8. d In the Poisson-binomial
model, gene alteration probabilities are estimated for each tumor individually. The expected number of alterations both per gene and per tumor
match the observed numbers. The product of two gene alteration probabilities is also computed per tumor. The expected number of tumors with
alterations in both genes according to this model is 1.5
We next evaluated the sensitivity of the binomial test.
For this, we tested simulated co-occurrences and mutual
exclusivities, which we added to the data. A sensitive test
should produce only low P values for these positive cases,
and so the resulting P-value distribution should be heav-
ily skewed towards zero. If we test for co-occurrences, this
is indeed the case (Fig. 2b). Testing for mutual exclusiv-
ity, however, reveals a distribution that, although skewed
towards lower P values, is muchmore stretched out across
the [0, 1] interval (Fig. 2d). Even highly liberal signifi-
cance levels will only recover a small part of the positive
cases.
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Fig. 2 Histograms of P values obtained on simulated data using either the binomial test (a–d) or the DISCOVER test (e–h). The P values apply to
gene pairs with three different types of relation: gene pairs with independent alterations (a, c, e, g), gene pairs with co-occurring alterations (b, f),
and gene pairs with mutually exclusive alterations (d, h)
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We conclude that the binomial test is anti-conservative
as a co-occurrence test. In contrast, as a mutual exclu-
sivity test, it is conservative. While we used the binomial
test for this illustration, we found the same to be true for
Fisher’s exact test (Additional file 1: Figure S1). To con-
firm our hypothesis that the i.i.d. assumption is causal
to this incorrect behavior, we generated additional sim-
ulated data, making sure that the overall alteration rate
was similar across the tumors. Using the binomial test
to detect co-occurrence and mutual exclusivity of inde-
pendent genes results in P-value distributions that are
much closer to uniform (Additional file 1: Figure S2).
This confirms that statistical tests that rely on the
i.i.d. assumption are not suited for co-occurrence anal-
ysis, and have reduced sensitivity for mutual exclusivity
analysis.
A novel statistical test for co-occurrence andmutual
exclusivity
Our new method, which we call Discrete Independence
Statistic Controlling for Observations with Varying Event
Rates (DISCOVER), is a statistical independence test that
does not assume identically distributed events. The main
ingredients of the method are depicted in Fig. 1d. Unlike
the method in the simpler binomial test, we allow differ-
ent tumors to have different alteration probabilities for the
same gene—the alteration probabilities for genes 3 and 5
in Fig. 1d now vary per tumor, in contrast to Fig. 1c. For
tumors with many altered genes, this probability is higher
than for tumors with only few alterations. To estimate
these alteration probabilities, we solve a constrained opti-
mization problem that ensures that the probabilities are
consistent with both the observed number of alterations
per gene and the observed number of alterations per
tumor. The probability of concurrent alterations in two
independent genes is then obtained for each tumor indi-
vidually, by multiplying the tumor-specific gene alteration
probabilities, as indicated in the right panel of Fig. 1d.
With these probabilities, an analytical test based on the
Poisson-binomial distribution can be performed to decide
whether the number of tumors altered in both genes
deviates from the expectation.
We repeated the simulation study performed for the
binomial test, this time applying the DISCOVER test.
First, our data only contained independently generated
alterations. Testing for co-occurrence (Fig. 2e) andmutual
exclusivity (Fig. 2g) resulted in P-value distributions much
closer to uniform, as one would expect. The fact that these
distributions are not truly uniform is a property shared
by all discrete test statistics [21]; it makes discrete tests
slightly more conservative. Most importantly, the anti-
conservative bias towards co-occurrence of the binomial
test is not present in the DISCOVER test. By testing sim-
ulated co-occurrences, we established that the removal
of the anti-conservative bias does not compromise the
sensitivity for true co-occurrences (Fig. 2f). Moreover,
the sensitivity for mutual exclusivities is improved when
compared with the binomial test (Fig. 2h).
Extension to a group-basedmutual exclusivity test
Mutual exclusivity is not restricted to pairs of genes.
Larger groups of genes may also display alteration pat-
terns in which most tumors only have an alteration in one
of the genes. We considered three statistics to assess the
mutual exclusivity of groups of genes: coverage, exclusiv-
ity, and impurity (Fig. 3a). For all three of these statis-
tics, its expectation for groups of independent genes
can be described by a Poisson-binomial distribution (see
Methods), and thus a statistical test can be formulated
for determining significance. Based on simulated data, we
established that the impurity-based group test has the best
balance between sensitivity and specificity (Additional
file 1: Figure S3).
Comparison to other mutual exclusivity tests
We compared the performance of the group-based DIS-
COVER test to that of several other published mutual
exclusivity tests: MEMo [6], muex [8], mutex [9], CoMEt
[10],MEGSA [11], andTiMEx [12]. In this comparison, we
focused on the statistical tests for mutual exclusivity pro-
vided by these methods (see Methods). Although the tests
differ in the statistical model upon which they are based,
all but MEMo assume identical alteration probabilities
across tumors. Like Fisher’s exact test and the binomial
test, they are thus examples of tests based on the i.i.d.
assumption.MEMo does take into account tumor-specific
alteration rates by preserving these rates in a permutation
scheme. Unlike DISCOVER, it estimates the alteration
rate with respect to a small set of recurrently altered genes
as opposed to all genes.
The comparison was performed on simulated data.
Groups of genes withmutually exclusive alterations of var-
ious degrees of impurity served as positive examples (see
Methods). For each such group, we also selected groups of
independent genes of the same size and matched to have
similar alteration frequencies, to serve as negative exam-
ples. In total, 10 data sets of 100 positive and 100 negative
groups were generated, and evaluation metrics were aver-
aged across these 10 sets. We evaluated the tests for both
specificity and sensitivity.
To evaluate specificity, we considered the extent to
which a chosen significance level α predicts the false pos-
itive rate obtained when groups with a nominal P value
less than α are classified as mutually exclusive. By defi-
nition of the P value, rejecting the null hypothesis at a
significance level α should guarantee that the false posi-
tive rate (or type I error rate in statistical terminology) is
at most α. Graphically, if the false positive rate is plotted as
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Fig. 3 Extension of the DISCOVER test for mutual exclusivity within groups of genes. a Three alternative statistics for measuring the degree of
mutual exclusivity within a group of genes. Coverage refers to the number of tumors that have an alteration in at least one of the genes. Exclusivity
refers to the number of tumors that have an alteration in exactly one gene. Impurity refers to the number of tumors that have an alteration in more
than one gene. b P-value reliability curves comparing DISCOVER with other mutual exclusivity tests. The false positive rate should not exceed the
significance level α. In such a case, the calibration curve will be below the diagonal. For all tests but muex, this is the case. The curves for CoMEt,
MEGSA, mutex, and TiMEx are mostly overlapping; their false positive rate stays at 0 until the significance level is almost 1. c Sensitivity curves
comparing DISCOVER with other mutual exclusivity tests. More sensitive tests will attain higher true positive rates at lower significance levels. Two
discontinuities that occur at a significance level of approximately 1 × 10−16 are marked with dotted lines. First, muex compresses all lower P values
to 0; hence, all lower significance levels have the same true positive rate. Second, this significance level coincides with the change from the slower
CoMEt exact test to the binomial approximation (see Methods); the two tests seem to behave quite differently
a function of the significance level (Fig. 3b), the resulting
curve would ideally follow the diagonal, or it should drop
below the diagonal for more conservative tests. With the
exception of muex, all methods control their false positive
rate below the nominal significance level, but they do so
in notably different ways. CoMEt, mutex, and TiMEx only
yield false positives at extremely high significance levels.
Doing so, they are more conservative than required. In
contrast, DISCOVER’s curve follows the diagonal more
closely. This is another confirmation that tests based on
the i.i.d. assumption—like before with the binomial and
Fisher’s exact tests—aremore conservative than those that
model the varying alteration rates. Indeed, MEMo is also
less conservative than CoMEt, mutex, and TiMEx. It is
more conservative than DISCOVER though, which may
be explained by the different strategies for estimating the
tumor-specific alteration rates: based on all genes for DIS-
COVER, or based on frequently altered genes only for
MEMo.
To evaluate sensitivity, we compared the increase of the
true positive rate as a function of the significance level
(Fig. 3c). A sensitive test will already attain high true pos-
itive rates at low significance levels. Across the whole
range of significance levels, DISCOVER was found to be
more sensitive than any of the other tests. It identified
more mutually exclusive groups at lower significance lev-
els. Only muex initially shows a higher sensitivity, but it
does so at the price of many false positives (Fig. 3b)—
we suspect this is partly due to numerical imprecision. At
higher significance levels, muex’s sensitivity drops below
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that of DISCOVER. MEMo only attains a high sensitivity
at higher significance levels: it is affected by the limited
resolution of its permutation test. We used 10,000 permu-
tations, which makes the lowest possible P value 1×10−4.
Again contrasting tests based on their underlying assump-
tion, we conclude that the conservatism caused by the
i.i.d. assumption is reflected in a lower sensitivity. The
majority of mutually exclusive groups are only identified
at relatively high significance levels. If correction for mul-
tiple testing is applied, this may render many of them
insignificant.
Co-occurrence andmutual exclusivity in pan-cancer
somatic alterations
We analyzed a set of 3386 tumors covering the 12 can-
cer types studied in the TCGA pan-cancer initiative [22].
An alterationmatrix was constructed from recurrent copy
number changes and high-confidence mutational drivers.
Copy number changes were analyzed for 118 genes, of
which 40 were gains and 78 were losses. In addition, muta-
tion data were added for 286 genes previously classified
as high-confidence driver genes [23]. In total 404 genomic
alterations were analyzed covering 374 unique genes, as
30 genes are frequently targeted by both copy number
changes and mutations.
We tested for pairwise co-occurrence and mutual exclu-
sivity between pairs of genes not located on the same
chromosome. These tests were stratified for cancer type to
avoid confounding due to cancer type-specific alteration
frequencies. Complementing the pairwise tests, we also
employed the DISCOVER group test to detect patterns of
mutual exclusivity in larger groups of genes. The groups
we tested were selected using two different approaches. In
the first approach, we extracted gene sets from the canon-
ical pathway collection of MSigDB [24]. We tested 23 such
gene sets based on pathway membership. In the second
approach, we aimed to detect de novo gene sets purely
based on the data. For this, we applied a clustering algo-
rithm to the pairwise mutual exclusivity results to identify
groups of genes showing a high degree of interaction.
No evidence for widespread co-occurrence
A remarkable outcome of our analysis is that we found no
evidence for widespread co-occurrence of somatic alter-
ations. At a maximum false discovery rate (FDR) of 1%, no
significant co-occurrences were identified. Relaxing the
FDR threshold to 3%, we could recover one co-occurrence,
between mutation of TP53 and amplification of MYC. It
was recently suggested that MYC-amplified tumors show
higher levels of MYC expression in tumors with a TP53
mutation than in tumors without [25]. No further, rea-
sonable relaxation of the significance threshold led to
additional hits. Certainly, more gene pairs exist that har-
bor alterations in overlapping sets of tumors. Yet, the
sizes of those overlaps do not exceed what is expected
by chance if differences in tumor-specific alteration rates
are taken into account. This is in sharp contrast with the
significance estimates obtained with the binomial test,
which identifies 21,627 significant co-occurrences, almost
one-third of all pairs tested.
With the aim of establishing that the DISCOVER test
is not overly conservative, we tested for co-occurrence
between copy number changes of genes on the same chro-
mosomes. Due to the inherent correlation in copy number
of genes situated close to each other, such gene pairs can
be considered positive controls. Indeed, all but one of the
112 pairs of tested genes located in the same recurrently
altered segment are identified as co-occurring by the DIS-
COVER test. In addition, 18 pairs of genes situated on
the same chromosome arm are detected as co-occurring,
as are DDAH1 on 1p22 and MCL1 on 1q21. More gener-
ally, pairs within the same segment are assigned lower P
values on average than are pairs within the same chromo-
some arm (P = 7 × 10−39, Additional file 1: Figure S4).
The same is true, to lesser extents, for pairs within the
same chromosome arm compared to pairs within the
same chromosome (P = 6 × 10−8) and for pairs within
the same chromosome compared to pairs across chromo-
somes (P = 0.0004).
Mutually exclusive alterations target core cancer pathways
Pairwise mutual exclusivities were found among 181 pairs
of genes, at a maximum FDR of 1% (Additional file 2:
Table S1). We once more confirmed that detecting mutual
exclusivities using the binomial test results in far fewer
significant mutual exclusivities—only three pairs were
identified. Among the 181 gene pairs, there were 107
unique genes. Many of these are significantly mutually
exclusive with only one or a few other genes. For some,
reduced statistical power due to low alteration frequency
may be the reason for not detecting more associations.
However, alteration frequency is not the dominant fac-
tor in how often mutual exclusivity is detected (Fig. 4a).
For example, mutations of KRAS are far less frequent
than TP53 or PIK3CA mutations. Yet, KRAS was found
mutually exclusive with more genes than were the latter
two genes.
Since mutual exclusivity is believed often to occur
between functionally related genes, we determined the
overlap of the identified gene pairs with the STRING
functional interaction network [26]. Thirty-one of the
identified gene pairs have a high-confidence functional
interaction in STRING (Fig. 4b). This overlap is signif-
icantly higher than the 5 overlapping pairs expected by
chance (P < 1 × 10−4), as determined using a permu-
tation test. Moreover, 121 of the mutually exclusive gene
pairs share a common interactor in the STRING network.
By chance, this is only expected to be the case for 80 gene
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Fig. 4 Overview of detected pairwise mutual exclusivities. a Comparison of the number of significant mutual exclusivities found for a gene and the
number of tumors in which it has been altered. bMutual exclusivities that overlap with high-confidence interactions in the STRING functional
interaction network depicted in their biological context. Red lines represent a mutual exclusivity between the connected genes. Dotted lines depict a
functional interaction
pairs (P = 0.003). This suggests that the mutual exclu-
sivities identified are indeed for a large part driven by
biological factors. Another confirmation of this is found
in the results of the MSigDB gene set tests (Additional
file 1: Figure S5). Twelve gene sets representing several
cancer-related pathways show significant mutual exclusiv-
ity. The mutual exclusivities that overlap with STRING
interactions revolve around three commonly deregulated
processes in cancer: growth factor signaling, cell cycle
control, and p53 signaling.
Growth factor signaling
Genes coding for proteins involved in growth factor sig-
naling are frequently altered in cancer. These alterations
display a high degree of mutual exclusivity. Mutations
targeting the receptor EGFR are mutually exclusive with
mutations in its downstream mediator KRAS. In turn,
KRASmutations are mutually exclusive with mutations in
its family member NRAS, its negative regulator NF1, and
its downstream effector BRAF. All of these alterations are
able to deregulate RAS signaling, and one is sufficient.
Mutual exclusivity of mutations in KRAS and mutations
in both PIK3R1 and PIK3CGmay be driven by the known
cross-talk between RAS signaling and phosphoinositide
3-kinase (PI3K) signaling [27].
The PI3K signaling cascade itself is also character-
ized by many mutually exclusive alterations. Mutations
in the PIK3CA and PIK3R1 genes—both coding for com-
ponents of the PI3K complex—are mutually exclusive.
Alterations in the PTEN gene—a negative regulator of
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the downstream activation of AKT by PI3K—are mutually
exclusive with mutations in PIK3CA, but also with alter-
ations in the upstream activator of the cascade ERBB2.
PI3K signaling is also the central biological process in sev-
eral of the gene sets found mutually exclusive with the
group-based test (Fig. 5a, Additional file 1: Figure S5).
Central genes in PI3K signaling such as SOS1, AKT1,
and AKT3 were not found as mutually exclusive with
other pathway members in the pairwise analysis, yet the
groupwise test correctly detects it.
Cell cycle control
Many tumors harbor alterations that disable the cell cycle
control present in healthy cells. This control arises from
a tightly regulated interplay between cell cycle-activating
cyclins and CDKs, and CDK inhibitors, linked together by
Fig. 5 Examples of gene sets with mutually exclusive alterations. The P values were computed using DISCOVER’s group-based test. Panels a and
b show predefined gene sets extracted from MSigDB. Panels c and d show gene sets identified using our de novo group detection approach
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the master cell cycle regulator RB1. Alterations in these
genes are also mutually exclusive. For example, copy num-
ber gains in Cyclins D1 and E1 are mutually exclusive, as
are CDKN2A copy number loss and both mutation and
copy number loss of RB1. The transcriptional activation
of CCND1 by MYC is also reflected in the mutual exclu-
sivity between copy number gains in the two genes. Also
as a group, cyclins, CDKs, and CDK inhibitors show a
clear pattern of mutual exclusivity (Fig. 5b, Additional
file 1: Figure S5). CDK4 and CDKN1B, central players in
the regulation of the cell cycle, did not appear in the pair-
wise results, but are highly exclusive with the other genes
involved.
p53 signaling
p53 plays a pivotal role in deciding on cell fate after cel-
lular stresses common in cancer development. For this
reason, p53 mutations are the most common alterations
in cancer. However, not all tumors disable p53 func-
tion genetically. Alterations in regulators of p53 provide
an alternative way to deregulate p53 function in p53-
wild-type tumors, but are likely redundant in tumors
that already have a dysfunctional p53 protein. Indeed, we
found alterations in several regulators of p53 to be mutu-
ally exclusive withTP53mutation. For example, mutations
in its positive regulator ATM, but also mutations in its
negative regulator HUWE1 are mutually exclusive with
TP53 mutations. MDM2 and MDM4, highly similar neg-
ative regulators of p53, have a mutually exclusive pattern
of copy number gains. Mutations in CASP8, a down-
stream mediator of p53-induced apoptosis, tend also not
to overlap with TP53mutations.
De novo gene set detection
As a final step in our analysis, we detected de novo gene
sets purely based on observed patterns of mutual exclu-
sivity, without input based on recorded biological knowl-
edge. To this end, we applied correlation clustering to a
network derived from pairwise mutual exclusivities (see
Methods). This identified 120 candidate mutually exclu-
sive gene sets. Testing these gene sets with DISCOVER, 43
were found to be mutually exclusive at a maximum FDR
of 1%. The full results are presented in the online Jupyter
notebooks (see Availability of data and materials). Below,
we discuss two interesting examples.
One of the most significant gene sets includes RB1 and
CDKN2A, two pivotal players in cell cycle control (Fig. 5c).
PARK2 [28],WWOX [29], FHIT [30], PTPRD [31, 32], and
MAPK12 [33] have also all been linked to a regulating role
in various phases of the cell cycle. They have been found
to do so by regulating cyclins, CDKs, or CDK inhibitors.
This functional similarity may explain these genes’ mutual
exclusivity with RB1 and CDKN2A. As of yet, LRP1B and
CSMD1 have not been linked to cell cycle control. Their
mutual exclusivity with respect to several regulators of the
cell cycle may instigate further study in this direction.
Another group of genes with a high degree of mutual
exclusivity (P = 7 × 10−8) consists of genes that have
been implicated in the regulation of Hedgehog signal-
ing (Fig. 5d). With the exception of ARHGAP35, all
genes in this group have experimentally been linked to
a regulatory role in Hedgehog signaling. GNAS [34, 35],
TBX3 [36], and WT1 [37] were found to directly reg-
ulate the pathway. ARID1A, coding for a component
of the SWI/SNF complex, is likely to play a similar
role, since loss of another component of this complex,
Snf5, was found to lead to activation of the Hedge-
hog pathway [38]. Besides these two examples, several
other gene sets were identified that combine known inter-
action partners with interesting leads for undiscovered
interactions.
Discussion
The recent growth in the number of large genomics
data sets gives rise to a parallel increase in statistical
power to detect ever more complex associations. How-
ever, as another consequence of larger sample sizes, poorly
matched assumptions will have an increasing impact on
the results. A central assumption behind commonly used
statistical tests for co-occurrence and mutual exclusivity
is that a gene’s alteration probability is identical across all
tumors. Using simulated data, we have shown that this
assumption is not only unjustified, but that it leads to a full
reversal of the associations. The binomial test we used for
illustration is but a representative of a larger class of inde-
pendence tests based on the same assumption. This class
includes analytical approaches such as Fisher’s exact test,
CoMEt [10], and MEGSA [11], but also permutation tests
where gene alterations are uniformly shuffled across the
tumors.
We have presented a novel independence test based
on assumptions that better match the reality of cancer
genomics data. With this new test, we analyzed tumors
across 12 different cancer types for the presence of co-
occurrence and mutual exclusivity. Only one case of co-
occurrence was found, whereas numerous cases of mutual
exclusivity were detected. Performing the same analy-
sis with the binomial test led to the detection of many
co-occurrences and almost no mutual exclusivity. Many
of the mutual exclusivities missed by the binomial test
can be related to central processes in cancer biology. We
found strong mutual exclusivity between genes involved
in growth factor signaling and cell cycle control. Also,
lesser known players in the regulation of cell cycle and
Hedgehog signaling were identified. Based on the results
of our simulation study, we are confident that most of
the co-occurrences detected by the binomial test are
spurious.
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The absence of widespread co-occurrence contradicts
what was found in previous genome-wide studies. Besides,
it seems counter to our expectation of positive selection
for synergy that led us to look for co-occurrence in the
first place. It is true that synergy resulting from the alter-
ation of multiple genes has been observed. Co-mutation
of genes has been reported to act on a tumor’s response
to chemotherapy, or more generally on patient survival
[39, 40]. None of these phenotypes, however, has been
the subject of the selection from which the original tumor
emerged. Only after selective pressure for that particu-
lar phenotype has taken place—for example, by treating
patients—would enrichment for such co-occurrences be
detected. There is no doubt that cancer-driving alter-
ations often act in concert. Yet if statistical results are
to serve as support for, or even meant to identify syn-
ergy, other possible explanations for the observed co-
occurrence should be accounted for. In our pan-cancer
analysis, overall alteration rates explained most if not all
co-occurrence.
The need to take into account higher level structural
features of samples is not unique for co-occurrence and
mutual exclusivity analysis. In testing the relationship
between high-dimensional gene expression data and phe-
notypes of interest, latent sources of heterogeneity can
have a profound effect on the results. Approaches like sur-
rogate variable analysis [41] have been developed to adjust
analyses appropriately. Similarly, genome-wide associa-
tion studies face the issue of latent population substruc-
ture. Again, if ignored, such substructure can drastically
alter the findings. Linear mixed models have gained pop-
ularity as a method to prevent confounding [42]. Both of
these examples have become standard methodologies in
many biomedical analyses.
Conclusions
Co-occurrence and mutual exclusivity of somatic alter-
ations are helpful concepts for the interpretation of cancer
genomics data. For example, hypotheses about functional
interactions between genes are often supported by sug-
gested co-occurrence or mutual exclusivity of their alter-
ations. Alarmingly, we have found that the statistical tests
most commonly used for this purpose are not appropri-
ate for testing the significance of co-occurrence. Many
gene pairs that are believed to be co-altered more often
than expected by chance do not exceed this expecta-
tion if the confounding effect of tumor-specific alter-
ation rates is taken into account. Hypotheses formulated
based on the results of those tests will therefore have
limited support from the data. For this reason, we dis-
courage the use of Fisher’s exact test or simple permu-
tation methods for detecting co-occurrence. We have
presented DISCOVER as a better alternative. Mutual
exclusivity analysis using existing tests does not suffer
from high false positive rates, but the sensitivity is low.
DISCOVER identifies more significant mutual exclusivi-
ties without increasing the false positive rate. Thus, for
both co-occurrence and mutual exclusivity analyses, we
expect future cancer genomics studies to benefit from
DISCOVER.
Methods
Independence statistic
We assess both co-occurrence and mutual exclusivity
by counting how many tumors have an alteration in
both genes and comparing this to the number of tumors
expected to have such an overlap by chance if these
alterations were independent. Importantly, the overlap
expected by chance should factor in the fact that tumors
with many alterations have a higher chance of such over-
lap than tumors with fewer alterations. Our null distri-
bution modeling this overlap therefore takes into account
both the alteration rate per gene and the alteration rate
per tumor. To this end, let pij denote the probability of an
alteration in gene i and tumor j. We assume that the alter-
ation probability of a gene is higher in tumors with many
alterations overall than in tumors with fewer alterations.
Therefore, pij may be different from pik for the same gene
i in two different tumors j and k. Then, for two indepen-
dent genes with alteration probabilities p1j and p2j, the
probability of an alteration in both genes in tumor j is
p1jp2j, while for tumor k it is p1kp2k . Given such probabil-
ities for a set of tumors, the number of tumors that have
an alteration in both genes follows a Poisson-binomial
distribution.
The Poisson-binomial distribution [43] describes
the sum of independent, non-identically distributed
Bernoulli random variables that have success probabilities
p1, p2, . . . , pn. Its probability mass function is defined as
follows:
P(X = x) =
∑
A∈Fx
⎛
⎝
∏
i∈A
pi
∏
j∈Ac
(1 − pj)
⎞
⎠
Here,Fx contains all subsets of size x of {1, 2, . . . , n}, and
Ac denotes the complement of A.
Based on this distribution, we can estimate the proba-
bility of observing a number of tumors with alterations in
two genes as extreme—as high for co-occurrence, or as
low for mutual exclusivity—as the one observed.
If, for a given gene i, all probabilities pij are equal
for every tumor j, then the Poisson-binomial distribution
reduces to a binomial distribution. However, estimating
an individual alteration probability for every single tumor
ensures that the heterogeneity in alteration rates across
tumors is taken into account.
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Estimating gene- and tumor-specific alteration
probabilities
To apply the DISCOVER test, we need estimates of the
alteration probabilities pij for all genes i and all tumors
j. Let X ∈ {0, 1}n×m denote the n × m binary alteration
matrix where an entry xij is 1 in case of an alteration in
gene i and tumor j, and 0 otherwise. We use the notation
xi• and x•j for the marginal sums of the ith row and jth
column, respectively. Furthermore, let Xij denote the ran-
dom variable for xij, and Xi• and X•j the corresponding
marginal sums. If we were to assume that the alteration of
a gene is equally likely across all tumors, then the alter-
ation probability only depends on the number of altered
tumors xi• and the total number of tumorsm:
pij = P
(
Xij = 1|xi• = k
) = km , ∀j
Estimating the alteration probabilities this way ensures
that the expected number of alterations Ep(Xi•) = ∑j pij
for a gene matches the observed number xi•. In fact, the
familiar expression above is the one that maximizes the
likelihood of the observed alterations under the constraint
that the expected number of alterations per gene matches
the observed number. To make this more explicit, we can
reformulate the probability estimation as a constrained
optimization problem:
max
p
Lp(X ) =
n∏
i=1
m∏
j=1
(
pijxij + (1 − pij)(1 − xij)
)
s.t.
pi1 = pi2 = . . . = pim , 1 ≤ i ≤ n
m∑
j=1
pij =
m∑
j=1
xij , 1 ≤ i ≤ n
0 ≤ pij ≤ 1 , 1 ≤ i ≤ n, 1 ≤ j ≤ m
All of the above is based on the assumption that alter-
ation probabilities for a gene are equal across tumors.
Symptomatic for this assumption are probability estimates
such that the expected number of alterations per tumor
Ep(X•j) = ∑i pij generally does not match the observed
number x•j. To take into account tumor-specific alteration
rates, the above optimization problem can be extended
such that this expectation is also matched:
max
p
Hp(X ) = −
n∑
i=1
m∑
j=1
(
pij log
(
pij
) + (1 − pij
)
log
(
1 − pij
))
s.t.
m∑
c=1
pic =
m∑
c=1
xic , 1 ≤ i ≤ n
n∑
r=1
prj =
n∑
r=1
xrj , 1 ≤ j ≤ m
0 ≤ pij ≤ 1 , 1 ≤ i ≤ n, 1 ≤ j ≤ m
With this new formulation, the number of parameters
to fit is increased by a factor m. As a consequence, opti-
mizing the likelihood Lp(X ) of the model risks overfitting
the data. Therefore, instead of optimizing the likelihood,
we choose to optimize the information entropy Hp(X ). It
can be shown that in the optimal solution to this reformu-
lated problem, each alteration probability can be written
in terms of two parameters (Additional file 1: Parameter
estimation):
pij = 11 + eμi+λj
Here, each parameter μi for gene i is shared by all
tumors, and each parameter λj for tumor j is shared by
all genes. Because of this, while the original optimization
problem aims to estimate n×m alteration probabilities, we
can obtain the optimal solution by estimating only n + m
parameters. Moreover, all genes with the same number of
altered tumors share the same value for μi. Likewise, all
tumors with the same number of altered genes share the
same value for λj. This sharing of parameters leads to an
even larger reduction in the effective dimensionality of the
optimization.
Unlike for the binomial case, there is no closed-form
solution for estimating the μi and λj parameters. Instead,
we use the quasi-Newton numerical optimization algo-
rithm L-BFGS [44].
Stratified analysis
When the data consist of clearly separate groups of
tumors, such as is the case in the pan-cancer analysis
with its different cancer types, it is preferable to stratify
the analysis on these groups. For example, in the mutual
exclusivity analysis, if group structure is not taken into
account, the detected mutual exclusivities may be little
more than markers for the underlying cancer types, rather
than biologically related genes. An example of this type of
confounding is presented in Additional file 1: Stratifica-
tion in pan-cancer analysis. The DISCOVER test is easily
stratified for different groups by solving the constrained
optimization problem separately for the tumors of each
group. The group-specific background matrices can then
be concatenated to construct a single global, but stratified,
parameter matrix.
More formally, the binary alteration matrix X can be
seen as a concatenation of several n × mc submatrices
Xc, where c ∈ {1, 2, . . . ,C} refers to one of C pos-
sible subgroups—e.g., a cancer type in the pan-cancer
analysis—andmc is the number of tumors in that group:
X = [X1 X2 . . . XC]
To illustrate this, Additional file 1: Figure S6a shows
an alteration matrix with tumors of two different sub-
types. The parameter estimation procedure described in
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the previous section is then applied to each submatrix
Xc individually, resulting in subgroup-specific probabil-
ity matrices Pc (Additional file 1: Figure S6b). The global,
stratified probability matrix is obtained by concatenating
these matrices:
P = [P1 P2 . . . PC]
As in the non-stratified case, the expected number of
alterations for each gene matches the observed num-
ber. However, unlike for the non-stratified probabilities,
the expected numbers also match the observed num-
bers within each subgroup. With this stratified probability
matrix, the Poisson-binomial test is applied in the same
way as in the non-stratified setting (Additional file 1:
Figure S6c).
False discovery rate control
Commonly used procedures for multiple testing correc-
tion assume that the P values are distributed uniformly
under the null hypothesis. This is the case for, e.g.,
Bonferroni correction and the Benjamini-Hochberg pro-
cedure. However, hypothesis tests that are based on a
discrete test statistic, such as our DISCOVER test, are
known to lead to non-uniform P-value distributions under
the null hypothesis. In fact, pooling the P values across
tests with a large set of different parameters results in
a P-value distribution that is skewed towards 1.0. This
complicates the application of the standard procedures
for multiple testing correction. While these procedures
would still control the familywise error rate or false dis-
covery rate at the specified threshold, they will be more
conservative because of the non-uniformity caused by the
discrete test statistic. For the analyses in this paper, we
used an adaptation of the Benjamini-Hochberg procedure
for discrete test statistics [45]. Further details on this pro-
cedure are provided in Additional file 1: False discovery
rate control for discrete tests.
Group-basedmutual exclusivity test
We have defined a family of group-based mutual exclu-
sivity tests. The following statistics can be used to assess
groupwise mutual exclusivity. Each of these statistics can
be shown to follow a Poisson-binomial distribution, which
we make use of to estimate significance.
• Coverage: the number of tumors that have an
alteration in at least one of the genes. Significance is
based on the probability of observing a coverage at
least as high in independent genes. The
Poisson-binomial parameters for a group of genes
{gi | i ∈ I} can be derived from the individual gene
alteration probabilities as follows:
pj = 1 −
∏
i∈I
(1 − pij) , 1 ≤ j ≤ m
That is, the probably of at least one alteration is one
minus the probability of not having any alteration.
• Exclusivity: the number of tumors that have an
alteration in exactly one of the genes. Significance is
based on the probability of observing exclusivity at
least as high in independent genes. The
Poisson-binomial parameters can be derived from the
gene alteration probabilities as follows:
pj =
∑
i∈I
pij
∏
k∈I\{i}
(1 − pkj) , 1 ≤ j ≤ m
• Impurity: the number of tumors that have an
alteration in more than one gene. Significance is
based on the probability of observing impurity at
least as low in independent genes. The
Poisson-binomial parameters can be derived from the
gene alteration probabilities as follows:
pj = 1 −
∏
i∈I
(1 − pij) −
∑
i∈I
pij
∏
k∈I\{i}
(1 − pkj) , 1≤ j≤ m
That is, the probability of more than one alteration is
one minus the probabilities of no alterations and
exactly one alteration. As a special case of this, if a
group of only two genes is tested, the above
expression reduces to pj = p1jp2j. This is the same
parameterization as was used for the pairwise test.
Simulation data
An alteration matrix was constructed such that alter-
ation frequencies across both genes and tumors resembled
those of real tumors. For this, we used the copy num-
ber data of the TCGA breast cancer study as a reference.
Based on the copy number matrix for 24,174 genes and
1044 tumors, we constructed two sequences of marginal
counts corresponding to the number of amplifications
across genes and across tumors. These two sequences
were used as degree sequences to construct a random
bipartite graph following the configuration model. The
adjacency matrix of this bipartite graph was then used
as the alteration matrix for the simulated data analyses.
Because of the way this matrix was constructed, the alter-
ation frequencies across both genes and tumors resemble
those of the breast cancer tumors used for reference, yet
there is no dependence between alterations across genes.
For the analyses, only genes with at least 50 alterations
were tested.
Mutually exclusive and co-occurring gene pairs, as well
as mutually exclusive gene sets, were generated based on
two parameters: coverage, the number of tumors altered
in at least one of the genes; and impurity or overlap,
the proportion of covered tumors altered in more than
one of the genes. To generate pairs of mutually exclusive
genes, we used quantile regression to relate the cover-
age of independent gene pairs to their impurity. Simulated
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mutually exclusive gene pairs were generated such that
their impurity was below the first percentile predicted by
the quantile regression model based on their coverage.
Likewise, pairs of co-occurring genes were generated such
that the number of tumors altered in both genes exceeded
the 99th percentile based on the coverage of independent
gene pairs.
Mutually exclusive gene sets were generated by first
constructing sets of purely mutually exclusive gene alter-
ations and then adding additional, non-exclusive alter-
ations to obtain a prespecified degree of impurity. For
the former, the percentage of covered tumors was ran-
domly sampled from a truncated normal distribution
with mean 0.4 and standard deviation 0.2, truncated on
the interval [0.2, 0.8]. Next, individual gene alteration
frequencies were sampled from the empirical distribu-
tion of alteration frequencies in the TCGA breast can-
cer matrix. Gene alteration frequencies were sampled
until their sum reached the coverage of the group. The
number of genes thus depends on the coverage in a
way that is based on realistic cancer data. As some of
the mutual exclusivity tests we compared with become
intractable with larger numbers of genes, we restricted
the maximum number of genes to 6. In addition, we
also used a minimum gene set size of 3. Finally, the
impurity was sampled from the set {0.02, 0.05, 0.08}.
Impure alterations, i.e., additional alterations in an already
covered tumor, were assigned to tumors with a prob-
ability proportional to the tumor’s overall alteration
frequency.
For all analyses, the background matrix for the DIS-
COVER test was estimated on the complete alteration
matrix, including genes with fewer than 50 alterations,
and including simulated co-occurrences or mutual exclu-
sivities.
Comparison to other mutual exclusivity tests
We compared the performance of the group-based
DISCOVER test to that of MEMo [6], muex [8], mutex
[9], CoMEt [10], MEGSA [11], and TiMEx [12]. Some of
these methods do more than just test for mutual exclusiv-
ity. They combine a statistical test for mutual exclusivity
with an algorithm that identifies groups of genes to test.
In our comparison, we were interested in comparing the
performance of the statistical tests only. We therefore
evaluated the mutual exclusivity tests by applying them to
preidentified groups of genes.
For muex, MEGSA, and TiMEx, we used the R imple-
mentations provided with their respective publications.
For CoMEt, we used a modified version of the official soft-
ware implementation. Due to the computational complex-
ity of the CoMEt test, it became intractable for some of the
gene sets in the comparison. For this reason, the CoMEt
publication suggests a set of heuristics to decide between
the exact test and a faster binomial approximation, but we
found those to be inadequate in our comparison. Instead,
we changed the implementation such that it interrupts
the CoMEt exact test after 1 minute and returns the P
value obtained with the binomial approximation. For the
MEMo and mutex tests, we used our own implementa-
tions, which we verified to give the same results as their
original Java implementations.
Pan-cancer alteration data
Preprocessed somatic mutation and copy number data
for the 12 cancer types studied in the TCGA pan-
cancer initiative [22] were obtained via Firehose (analysis
run 2014_07_15 at http://gdac.broadinstitute.org/runs/
analyses__2014_07_15/). Mutations were extracted from
the input of the MutSig 2CV analysis. Mutations for genes
that have previously been identified as high-confidence
mutational drivers [23] were included in the analysis. Dis-
cretized copy number changes were extracted from the
output of GISTIC2. We considered genes altered if GIS-
TIC2 qualified their copy number change as high level.
Pan-cancer recurrently altered regions were obtained
via Synapse (syn2203662 at https://www.synapse.org/#!
Synapse:syn2203662). For each region, we selected their
most likely driver genes for inclusion in the analysis. If a
region contained only one gene, this gene was assumed
its driver. In the case of more genes, genes were selected
if they overlapped with the list of high-confidence muta-
tional driver genes, or with a curated list of cancer genes
(http://www.bushmanlab.org/links/genelists).
Background matrices for the DISCOVER test were
estimated for each type of alteration—mutation, ampli-
fication, and deletion—separately, and based on the
genome-wide alteration matrices before gene selection.
Stratification for the 12 different cancer types was applied
as described before. The background matrix used in the
analysis was subsequently composed from the relevant
rows in the three alteration type-specific background
matrices.
Overlap with the STRING functional interaction network
Version 10.0 of the STRING network [26] was used
to determine overlap of detected mutual exclusivities
and functional interactions. We constructed a functional
interaction graph by connecting genes with an edge if they
had a high-confidence STRING interaction, defined by a
combined score greater than 800. A mutual exclusivity
graph was constructed by connecting genes with an edge
if alterations in these genes were found mutually exclu-
sive at a maximum FDR of 1%. The overlap corresponds to
the number of edges appearing in both graphs. To deter-
mine the enrichment of this overlap, we estimated a null
distribution by randomly shuffling the gene labels of the
mutual exclusivity graph 10,000 times and computing the
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overlap of these shuffled mutual exclusivity graphs with
the unshuffled functional interaction graph.
De novo gene set detection
Our algorithm for detecting de novo sets of mutually
exclusive genes combines two ideas from community
detection. Its goal is to detect gene sets with a high like-
lihood of being mutually exclusive based on the results
of a pairwise mutual exclusivity analysis. There are three
main steps. First, a mutual exclusivity graph is constructed
where genes are connected by an edge if their alterations
have been identified as mutually exclusive by the pair-
wise test. For this step, we used a permissive significance
criterion—a maximum FDR of 10%—so as not to exclude
potentially interesting gene pairs that may simply not have
reached significance due to the limited sample size. Sec-
ond, groups of genes with a high density of mutual exclu-
sivity edges between them are identified using a graph
partitioning algorithm. Finally, these groups are subjected
to the groupwise mutual exclusivity test to retain only
those groups that are mutually exclusive as a group.
The graph partitioning step is based on overlapping cor-
relation clustering. In correlation clustering, nodes in a
graph are clustered such that the combined weight of
edges within clusters is maximized and the combined
weight of edges between clusters is minimized. The par-
ticular algorithm we used [46] allows nodes to be assigned
to multiple clusters. Moreover, we modified the original
algorithm such that groups of nodes can be designated
that should always share the same cluster assignments.
We used this for two situations. First, genes in the same
copy number segment have highly correlated copy num-
ber alterations and, consequently, highly similar mutual
exclusivities. Purely based on genomic data, there is no
reason to prefer one gene over the other, which is why we
always assign all such genes to the same cluster. Second,
we assume that copy number alterations and mutations
targeting the same gene serve the same function, and
therefore add the constraint that these are always assigned
to the same cluster.
The edge weights of the mutual exclusivity graph play
an important role in the objective function of corre-
lation clustering. A common phenomenon in pairwise
associations is that one gene is found mutually exclu-
sive with many other genes, but those genes are not all
mutually exclusive with each other. The edges connect-
ing the former gene may therefore not be indicative of
gene set membership. They should be assigned a lower
weight than edges that more specifically connect genes
with a high degree of internal connectivity. To this aim,
we selected the edge weights to optimize a modularity
objective. In modularity optimization, a graph is com-
pared with random graphs having the same number of
nodes, edges, and degree distribution. Edges that are
specific to the graph being partitioned are preferably
kept within clusters, whereas edges that also appear in
many of the random graphs will often span two clus-
ters. We used a modularity measure based on conditional
expected models [47]. This measure ensures that edges
connecting sets of nodes with high node degrees receive
a lower weight than edges that connect sets of nodes
with low node degrees. It also allows for the covariance
between the mutual exclusivity tests to be taken into
account.
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